Dysregulation of the peripheral immune system is be involved in the neuroinflammation in Alzheimer disease (AD) and accelerate the disease progression. The contribution of immune cells, particularly B cells, to AD pathogenesis has gained attention in recent research. In this study, we investigated the role of Peripheral Blood Memory B cells (PBMBs) and their secreted Migration Inhibition Factor (MIF) in driving macrophage behavior in AD based on the scRNA-seq technique, immunofluorescence and flow cytometry. We discovered that MIF binds to the CD74-CD44 receptor complex on macrophages, influencing their behavior. The dysregulated macrophage response hampers the clearance of amyloid-beta (Aβ) plaques, exacerbating AD pathology. Targeting the MIF-CD74-CD44 signal pathway may hold therapeutic potential in modulating macrophage activity and mitigating neuroinflammation in AD. This study provides a further understanding of peripheral immune cells dysregulated in AD.
27 October 2013 in American Journal of Alzheimer's Disease and Other Dementias®
Background: To assess whether biomarker τ protein could differentiate between Alzheimer’s disease (AD) and vascular dementia (VaD). Methods: We conducted a comprehensive search to identify studies on τ protein, patients with AD, and patients with VaD. Cerebrospinal fluid (CSF) τ protein levels were compared to discriminate among patients with AD, healthy controls, and patients with VaD by a meta-analysis. Results: Patients with AD exhibit significantly higher CSF τ protein levels than healthy controls or patients with VaD in the Chinese population. Conclusion: Our findings suggested that CSF τ protein levels were found to be significantly associated with AD in the Chinese population. Measurement of τ protein could help in attenuating the strict distinction between AD and VaD.
Background: Mitochondrial dysfunction and lipid metabolism dysregulation represent early key events in Alzheimer's disease (AD), yet integrated transcriptomic signatures combining these two biological processes for AD diagnosis remain poorly defined. Objective: This study aimed to construct and validate a mitochondrial-lipid metabolism (MLM) gene-based diagnostic classifier for AD using machine-learning approaches and explore its underlying biological mechanisms. Methods: Two public GEO datasets GSE5281 (training) and GSE28146 (independent validation) were included. Candidate MLM genes were retrieved from MSigDB. Differentially expressed MLM genes were screened by limma, followed by two-step feature selection with LASSO regression and random forest. Four machine-learning algorithms were compared. Model performance was evaluated by AUC, calibration, decision-curve analysis and subgroup analysis across AD severity. GSVA and hypergeometric test were applied for mechanistic exploration. Results: A five-gene signature ( SDR16C5, EGR1, ASAH2B, HIP1R, CKMT1B ) was finally identified. Logistic regression model achieved 5-fold cross-validated AUC of 0.953 in training cohort and AUC = 0.892 (95%CI:0.768–1.000) in validation cohort. The signature maintained high diagnostic accuracy across incipient, moderate and severe AD stages. Hypergeometric test demonstrated significant MLM-set enrichment (p = 3.85 × 10 −5 ). GSVA revealed close correlations between this signature with oxidative stress, synaptic dysfunction and apoptosis pathways. Conclusions: This validated five-gene MLM signature exhibits favorable diagnostic performance for AD and reflects disturbed mitochondrial-lipid metabolic network. It provides a promising transcriptomic biomarker for AD diagnosis.